<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574534</url>
  </required_header>
  <id_info>
    <org_study_id>BASKET-SMALL2</org_study_id>
    <nct_id>NCT01574534</nct_id>
  </id_info>
  <brief_title>Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions</brief_title>
  <acronym>BASKET-SMALL2</acronym>
  <official_title>A Prospective, Randomized, Controlled, Open Label, Multicenter Trial to Test the Non-inferiority of Drug Eluting Balloon vs. Drug Eluting Stent Treatment in de Novo Stenoses of Small Native Vessels Regarding Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Unit, University Hospital Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that in a real-world population undergoing percutaneous
      coronary intervention (PCI) for de-novo stenoses in small native vessels with a diameter &lt;3
      mm, drug eluting balloons (DEB) are non inferior to third-generation drug eluting stents
      (DES).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-eluting balloons are an established treatment for in-stent stenoses and showed good
      results in small vessels. Moreover, the available data suggest that DEB are a promising new
      technique for the treatment of de-novo stenoses in small vessels if pre-dilatation is
      performed and geographical mismatch is avoided.

      The aim of this study is to demonstrate that DEB is non-inferior to DES in a real-world
      population with respect to the combined clinical endpoint Major adverse cardiac events
      (MACE), defined as cardiac death, non-fatal myocardial infarction, and target vessel
      revascularization after 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>12 month</time_frame>
    <description>Major adverse cardiac events (MACE), defined as cardiac death, non-fatal myocardial infarction, and target vessel revascularization after 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>24/36 month</time_frame>
    <description>MACE after 24 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization</measure>
    <time_frame>12/24/36 month</time_frame>
    <description>The single components of the primary endpoint including target lesion revascularization after 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>12/24/36 month</time_frame>
    <description>Possible, probable, and definite stent thrombosis defined according to the ARC criteria after 12, 24, and 36 months; all stent thromboses defined according to the ARC criteria after 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis In Myocardial Infarction</measure>
    <time_frame>12/24/36 month</time_frame>
    <description>Thrombolysis In Myocardial Infarction (TIMI) major bleeding after 12, 24, and 36 months
Net clinical benefit consisting of the primary endpoint and the TIMI major bleeding after 12, 24, and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>12/24/36 month</time_frame>
    <description>Cost-effectiveness of DEB vs. DES after 12, 24, and 36 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">758</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Drug eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting balloon</intervention_name>
    <description>PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany</description>
    <arm_group_label>Drug eluting balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting stent</intervention_name>
    <description>PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA</description>
    <arm_group_label>Drug eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angina pectoris Canadian Cardiovascular Society (CCS) 2 to 4 or silent ischemia as
             assessed by stress echocardiography, stress cardiac magnetic resonance, myocardial
             perfusion scintigraphy, or fractional flow reserve

          -  PCI of de-novo stenosis in vessels ≥2.0 to &lt;3.0 mm in diameter irrespective of the
             indication (concomitant PCI of a vessel ≥3.0 mm in diameter is permitted if the
             stenosis is located in a coronary artery other than the culprit vessel)

          -  No flow-limiting dissection (TIMI ≤2) or residual stenosis &gt;30% after initial
             dilatation with a standard or non-compliant balloon, as assessed by the physician in
             charge

          -  Written informed consent

        Exclusion Criteria:

          -  Concomitant large-diameter PCI in the same coronary artery (LAD, Ramus circumflexus
             (RCX), RCA)

          -  PCI of instent-restenosis (culprit lesion)

          -  Life expectancy &lt;12 months

          -  Pregnancy

          -  Enrolled in another coronary intervention study

          -  Unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raban V Jeger, PD Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raban V Jeger, PD Dr</last_name>
    <phone>+41612655214</phone>
    <email>raban.jeger@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Graz Kardiologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Zweiker, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology, Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Alexander Ohlow, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin, Dept. Internal Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonhard Bruch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Kardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Krackhardt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Westfalen GmbH Knappschaftskrankenhaus</name>
      <address>
        <city>Dortmund</city>
        <zip>44309</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Farah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes - Kardiologie, Angiologie und internistische Intensivmedizin</name>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Scheller, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Möbius-Winkler, PD Dr med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH, Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Mangner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine/Cardiology, University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Wöhrle, Prof. Dr. med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raban V Jeger, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology Cantonal Hospital Baselland Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Leibundgut, MD</last_name>
      <phone>061 925 23 65</phone>
      <email>Gregor.Leibundgut@ksbl.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florim Cuculi, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology, Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Weilenmann, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

